. Author manuscript; available in PMC: 2023 Mar 17.

Published in final edited form as: Ophthalmology. 2015 May 9;122(7):1426–1437. doi: 10.1016/j.ophtha.2015.04.006

Table 4.

Patient Demographics and Characteristics at 24 Weeks for Second 4 Randomization Groups

Characteristic	Branch Retinal Vein Occlusion			Central Retinal Vein Occlusion
Characteristic	Ranibizumab plus Laser (n = 20)	Ranibizumab (n = 19)	P Value	Ranibizumab plus Laser (n = 18)	Ranibizumab (n = 20)	P Value
Mean age (yrs)	69.8 ± 2.2	66.3 ± 2.1	0.33	56.3 ± 3.4	66.2 ± 2.3	0.02
No. of women (%)	8 (40.0)	9 (47.4)	0.89	6.0 (33.3)	11.0 (55.0)	0.31
Disease duration (mos)	16.8 ± 5.5	12.2 ± 2.9	0.99	15.3 ± 3.1	16.1 ± 3.3	0.98
2.0-mg Ranibizumab group (no. of patients)	10	9		9	10
0.5-mg Ranibizumab group (no. of patients)	10	10		9	10
BCVA letter score (Snellen equivalent)	69.9 ± 3.1 (20/40)	60.8 ± 2.9 (20/63)	0.04	63.1 ± 3.3 (20/50)	61.7 ± 4.4 (20/50)	0.92
CST (μm)	311.4 ± 18.7	347.7 ± 31.6	0.82	323.0 ± 19.6	309.8 ± 32.5	0.16

BCVA = best-corrected visual acuity; CST = central subfield thickness.